Compare ARK Fintech Innovation ETF (ARKF) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Fintech Innovation ETF vs Illumina, Inc. — how do they compare? ARK Fintech Innovation ETF trades at $42.86, while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Illumina, Inc. is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKF | ILMN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $205.10 |
52-Week Low | $36.14 | $91.00 |
Market Cap | — | $29.12B |
Enterprise Value | — | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $42.54, up 1.48% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has underperformed the S&P 500, down 23% since July 2025, and faces elevated volatility. Recent news highlights its fintech and crypto exposure amid market consolidation, with a Hold rating due to fair valuation concerns.
Outlook remains cautious; high P/E of 33x and PEG of 2.0x suggest overvaluation risks, while sector consolidation offers potential recovery if market sentiment improves. Key risks include sustained underperformance and portfolio volatility, requiring careful monitoring of fintech sector trends.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
